Core Vct I Share Discussion Threads

[the stigologist] 06/4/2018 14:51

PYC £3m (Physiomics - AIM)
SLP $300m (Simulations Plus - Nasdaq)
CER $850m (Certara - Private)

[the stigologist] 06/4/2018 14:51

PYC £3m (Physiomics - AIM)
SLP $300m (Simulations Plus - Nasdaq)
CER $850m (Certara - Private)

[gimmetheloot] 06/4/2018 14:25

PSL on news of Halycon rollout with IBM already on board will multibag. Potential to 5-10 bag on news ;-)))

This tech is unique and will be rolled out globally.

[ianio5691] 06/4/2018 14:07

LOGP.
recent RNS re long awaited farmout of Barryroe oilfiled.
RNS this morning of placement to resolve outstanding funding.

Free float gone, and moving up from pm auction now.

[cpap man] 06/4/2018 13:23

VLS



Another one that is looking to really fly northwards is VLS

[cudmore] 06/4/2018 13:03

PEB......10p short term on this mornings RNS. Up 250% already but was up 400% earlier. Multibagger in the making

[cpap man] 06/4/2018 12:32

AST



Are AST over sold at these [low] levels?!?!?

[cpap man] 06/4/2018 11:40

KOD



Another ISA fav namely KOD

[billiondollarbrain] 06/4/2018 11:32

Shares Magazine
Small caps poised for big news in 2018:
We look at 19 stocks primed to deliver major events in their career
21/12/2017



"The pharmaceuticals space in 2018 is jam-packed with potentially game-changing clinical trial results.

Drug developer ImmuPharma (IMM:AIM) is expecting Phase III results in the first quarter of 2018 for lupus treatment Lupuzor. Analysts speculate the drug could hit multi-billion dollar annual sales if the tests are successful and the drug gets approved by the regulators."


This promising small-cap stock could be a millionaire maker in 2018
Paul Summers
26/12/2017



The suggestion that a single stock could lead some investors to become millionaires next year may sound fanciful but I think this is quite possible if events work out for small-cap drug discovery and development firm ImmuPharma (LSE: IMM). Let me explain.

Blockbuster potential

Over the last three months, shares in the AIM-listed company have climbed more than 200% in value as anticipation grows over the outcome of a Phase III clinical trial for Lupuzor — its 100%-owned potential treatment for Lupus.

Approximately five million people are believed to suffer from the chronic and potentially life-threatening autoimmune disease that can be a notoriously difficult to treat. In the last 50 years, only one therapy — GlaxoSmithKline‘s Benlysta — has been approved for use, despite its questionable efficacy and serious side-effects. In 2015, the drug achieved sales of over $400m. By 2020, this figure is expected to rise to $1bn.

Positively, data from Lupozor’s Phase IIb trial indicated that ImmuPharma’s treatment — which modulates rather than blocks the immune system — was both effective and safe. Moreover, the effectiveness of Lupuzor increased even after the three-month trial’s conclusion. Investors will be hoping that the 52-week, randomised and double-blinded study currently in progress (involving patients in the US, Europe and Mauritius) yields similar results.

In its most recent update on 21 December, the company revealed that all 200 participants had now received the full 12-month dosage and that the “robust safety record” shown in earlier trials continues to be seen. According to Chairman Tim McCarthy, the company looks forward “with continued confidence” to reporting on top-line results in Q1 of next year.

In the event of a positive outcome, ImmuPharma will then seek to exploit its Fast Track designation and push for approval from the Food and Drug Administration (FDA). Once received, the company would then be free to seek out a global licensing deal for taking Lupuzor to market or — perhaps more likely — consider takeover bids by deep-pocketed pharmaceutical giants at a price befitting its blockbuster potential. Given the suggestion that it could be used in the treatment of other diseases, the price could easily be in the billions of pounds. Right now, ImmuPharma’s market cap is a little over £200m.

Tempted? If so, it’s vital to consider the flip side of this investment.

Despite the encouraging outcomes of previous trials, the possibility of the drug failing to impress still remains. Plenty of highly promising treatments have disappointed at the last hurdle, resulting in significant capital losses for investors. Unless you’re willing to embrace this level of risk, Immupharma shouldn’t even make it on to your watchlist, let alone into your portfolio.

That’s why — as a holder of its stock — only a small proportion of my capital is invested in the company. This money can be lost. I might grumble and curse but — thanks to a degree of diversification — I won’t lose my shirt.

That said, if — and it remains a sizeable ‘if‘ — Lupuzor proves effective (or at least more efficacious than Benlysta), I’m confident that ImmuPharma could generate huge wealth for investors in a very short time period.

No investment is devoid of risk but only you can decide whether this is one worth taking.

[cpap man] 06/4/2018 10:59

WRES



Talking about the new tax year [6th April 2018] shares such as WRES must be a top pick for the new ISA season [up to £20K per person]

[cpap man] 06/4/2018 10:37

WRES



WRES could well go to 1.5p+

And perhaps more as at circa 2p the MKT CAP would be about £100M which could make sense with what WRES are doing?!?!?

[cpap man] 06/4/2018 10:09

You're obviously in the U.K.

[nicosevos] 06/4/2018 09:45

And to you...At least the sun is out this Morning, rain later.....

[cpap man] 06/4/2018 09:01

Kali Maera!

[nicosevos] 06/4/2018 08:54

Happy New Tax Year, to you all......

[cpap man] 06/4/2018 08:35

UOG



New ISA season starts today - up to £20K per person - with IMHO shares like UOG making perfect ISA holdings!

[yawn3] 05/4/2018 08:05

EVRH

Tick Tick. More good news.